Neural Analytics Secures $22 Million Series C Funding to Advance Robotic Platform for Brain Health Assessment

VCBeat (WeChat Official Account: vcbeat) has learned that on May 8, medical robotics company Neural Analytics announced the completion of a $22 million Series C financing round led by Alpha Edison.

Neural Analytics was spun out from the University of California, Los Angeles (UCLA) and established as an independent company in 2013. To date, Neural Analytics has raised $66 million, primarily from two venture capital firms: UCLA Ventures and Alpha Edison. In 2018, the company secured $15 million in a Series B financing round led by Alpha Edison.

Neural Analytics is a medical robotics company dedicated to developing and commercializing technologies for monitoring brain health. The company’s Lucid Robotic System, which integrates the Lucid™ M1 Transcranial Doppler Ultrasound System with the NeuralBot™ System, is a robot-assisted ultrasound platform designed for brain health assessment. This all-in-one robotic neurovascular ultrasound device enables neurologists to non-invasively locate and measure cerebral blood flow parameters. Leveraging its advanced capabilities in ultrasound, robotics, and machine learning, the system provides clinicians with critical insights into brain health, supporting informed clinical decisions to improve patient outcomes.

The Lucid robotic system not only supports initial neurological assessments but also provides services such as cerebral blood flow velocity monitoring and microemboli detection. Currently, the Lucid robotic system is actively deployed in healthcare institutions across the United States, and Neural Analytics will continue to drive its commercialization.

“Over the past six years, we have been dedicated to developing and validating new technologies, culminating in the creation of Lucid Robot, an impactful product. With this round of financing, Neural Analytics will be able to advance the Lucid Robot System into the clinical phase. We believe that in the near future, it will have a significant and positive impact on patient treatment outcomes,” said Leo Petrossian, CEO of Neural Analytics, in a statement.

“Over the past year, the company has secured U.S. FDA approval and European CE certification for its revolutionary platform. This platform leverages machine learning and robotics to accurately and rapidly identify key neurological disorders. We believe that by providing healthcare professionals with new technologies in the future of data-driven diagnostics, the company will better serve patients and advance the progress of medical care,” said Nick Grouf, Executive Partner at Alpha Edison.

Alpha Edison is an early-stage venture capital firm that primarily invests in technology-driven innovative enterprises to build industry-transforming technology platforms. The firm is committed to sharing its research insights and expertise in business model innovation with its portfolio companies, helping founders expand into new markets, unlock latent demand, and develop businesses that change the world.

(Compiled by: Wang Yue)